BLISSGVS

Bliss GVS Pharma Share Price

₹128.80 +8.14 (6.75%)

21 Nov, 2024 14:30

SIP TrendupStart SIP in BLISSGVS

Start SIP

Performance

  • Low
  • ₹120
  • High
  • ₹131
  • 52 Week Low
  • ₹92
  • 52 Week High
  • ₹150
  • Open Price₹122
  • Previous Close₹121
  • Volume2,661,772

Investment Returns

  • Over 1 Month -7.24%
  • Over 3 Month + 7.61%
  • Over 6 Month + 16.67%
  • Over 1 Year -7.2%
SIP Lightning

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.4
  • PEG Ratio
  • -0.8
  • Market Cap Cr
  • 1,357
  • P/B Ratio
  • 1.4
  • Average True Range
  • 6.74
  • EPS
  • 7.99
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -1.62
  • RSI
  • 46.43
  • MFI
  • 44.38

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹128.80
+ 8.14 (6.75%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹122.94
  • 50 Day
  • ₹124.31
  • 100 Day
  • ₹122.36
  • 200 Day
  • ₹118.04

Resistance and Support

121.85 Pivot Speed
  • R3 128.31
  • R2 126.55
  • R1 123.61
  • S1 118.91
  • S2 117.15
  • S3 114.21

What's your outlook on Bliss GVS Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities.

Bliss Gvs Pharma has an operating revenue of Rs. 800.17 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 15% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -15% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-07-24 Quarterly Results
2024-05-02 Audited Results & Final Dividend
2024-01-23 Quarterly Results
2023-11-01 Quarterly Results

Bliss GVS Pharma F&O

Bliss GVS Pharma Shareholding Pattern

34.82%
0%
6.56%
12.13%
34.57%
11.92%

About Bliss GVS Pharma

  • NSE Symbol
  • BLISSGVS
  • BSE Symbol
  • 506197
  • Managing Director
  • Mr. Gagan Harsh Sharma
  • ISIN
  • INE416D01022

Similar Stocks to Bliss GVS Pharma

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹128 As on 21 November, 2024 | 14:16

The Market Cap of Bliss GVS Pharma is ₹1356.7 Cr As on 21 November, 2024 | 14:16

The P/E ratio of Bliss GVS Pharma is 21.4 As on 21 November, 2024 | 14:16

The PB ratio of Bliss GVS Pharma is 1.4 As on 21 November, 2024 | 14:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23